SCHEMBL14723533

SCHEMBL14723533

N#Cc1cc(C(F)(F)F)cc2c1cnn2C1CCCCO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 3/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
RET P07949 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
GRIN1 Q05586 2/20 0.34
GRIN2B Q13224 2/20 0.34
AR P10275 5/20 0.33
FGFR1 P11362 1/20 0.32
DDR2 Q16832 1/20 0.32
PDE4D Q08499 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
SCN9A Q15858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29936967 0.83 RXRA (0.40) ATRRXRARXRBRXRGCYP4F2
SCHEMBL14722651 0.83 RXRA (0.40) ATRRXRARXRBRXRGCYP4F2
SCHEMBL31162513 0.82 ATR (0.41) ATRRXRARXRBRXRGCYP4F2
SCHEMBL14723051 0.82 ATR (0.41) ATRRXRARXRBRXRGCYP4F2
SCHEMBL14723281 0.81 RXRA (0.40) ATRRXRARXRBRXRGCYP4F2
SCHEMBL15208817 0.79 KCNH2 (0.41) ATRRXRARXRBRXRGCYP4F2
SCHEMBL14722997 0.78 RXRA (0.41) ATRRXRARXRBRXRGCYP4F2
SCHEMBL15229935 0.76 RXRA (0.35) ATRRXRARXRBRXRGCYP4F2
SCHEMBL25242455 0.76 RXRA (0.42) ATRRXRARXRBRXRGCYP4F2
SCHEMBL30444945 0.76 RXRA (0.42) ATRRXRARXRBRXRGCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748159-A1 SERINE/THREONINE PAK1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-07-02 EP disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 US disclosed
WO-2013026914-A1 SERINE/THREONINE PAK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 ATR 128/4885RXRA 1879/4885RXRB 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.